Two repair compounds constantly compared and frequently combined. Same evidence tier, and the dose scales are nothing alike.
Neither has a completed published human efficacy trial. Both sit in our preclinical tier, and that is the honest headline. Preclinical work on BPC-157 has focused on tendon, ligament and gastrointestinal healing; TB-500 work on cell migration and tissue remodelling. That reflects what has been studied, not a proven difference in people.
| BPC-157 | TB-500 | |
|---|---|---|
| What it is | Body Protection Compound 157, PL 14736 | Thymosin Beta-4 fragment (Ac-SDKP region) |
| Evidence tier | Preclinical | Preclinical |
| Route | Subcutaneous | Subcutaneous |
| Half-life | ~4 h (preclinical) | ~2–3 h (parent Tβ4) |
| Vial sizes | 5/10 mg | 10 mg |
| Water we suggest | 3 mL, 3 mL | 2 mL |
| Reported doses | 200 mcg, 250 mcg, 500 mcg, 10 mcg/kg | 2 mg, 2.5 mg, 2 mg, 42 mg (cardiac trial) |
| Has a schedule | no | Loading and maintenance phases |
BPC-157 is dosed in micrograms, TB-500 in milligrams — roughly a tenfold difference in mass. Mix both to the same volume and the draws are nothing alike, which is an easy and expensive mistake.
Full-length thymosin beta-4 reached human trials for dry eye and cardiac indications. TB-500 is a truncated fragment, not that molecule. Citations to the Tβ4 clinical programme are frequently presented as evidence for TB-500, and they are not the same compound.